Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease

Martinus A. Cozijnsen, Johanna C. Escher, Anne Griffiths, Dan Turner, Lissy De Ridder*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations

Abstract

Since the introduction of anti-tumor necrosis factor (TNF) therapy as treatment of inflammatory bowel disease (IBD), care of pediatric and adult patients with IBD has significantly improved. To further improve treatment efficacy and durability, multiple trials have compared the efficacy of combination therapy, using anti-TNF therapy combined with an immunomodulator (a thiopurine or methotrexate), with that of anti-TNF monotherapy with contradicting results. The safety of combined therapy has been questioned after several reported cases of hepatosplenic T-cell lymphoma in young patients with IBD so treated. Physicians prescribing anti-TNF therapy to patients with IBD are required to weigh the benefits of combined therapy with its risks. To inform physicians treating children with IBD of these benefits and risks, we reviewed studies in pediatric and adult patients with IBD comparing efficacy, durability, and/or safety of combined therapy with anti-TNF monotherapy.

Original languageAmerican English
Pages (from-to)951-961
Number of pages11
JournalInflammatory Bowel Diseases
Volume21
Issue number4
DOIs
StatePublished - 6 Mar 2015

Bibliographical note

Publisher Copyright:
Copyright © 2015 Crohn's & Colitis Foundation of America, Inc.

Keywords

  • biologic therapies
  • immunomodulators
  • inflammatory bowel disease
  • pediatric

Fingerprint

Dive into the research topics of 'Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this